GLG LLC’s Madrigal Pharmaceuticals MDGL Stock Holding History

GLG LLC’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,429	Closed	-$97K	–	650
2015 Q1	$97K	Buy	+1,429	New	+$123K	﹤0.01%	596

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GLG LLC's MDGL Position: Q2 2015 in Review

GLG LLC sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2015, closing a stake of 1,429 shares — an estimated $97K sold.

GLG LLC first reported a position in MDGL in Q1 2015 and held it in 1 quarter. The position peaked at $97K in Q1 2015. 97 funds tracked by Wall St. Rank hold MDGL as of Q2 2015.

GLG LLC reported no remaining Madrigal Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
GLG LLC sold 1,429 Madrigal Pharmaceuticals shares in Q2 2015, an estimated $97K.
GLG LLC first reported a position in Madrigal Pharmaceuticals in Q1 2015 and held it in 1 quarter.
GLG LLC's Madrigal Pharmaceuticals position peaked at $97K in Q1 2015.
97 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2015.

Based on GLG LLC's 13F filing for Q2 2015, filed 14 Aug 2015.